Table 3

Changes in appropriate disease management in the year before and the year after publication of the National Service Framework for Coronary Heart Disease.

BaselineFollow-up
Group A: CHD or strokenPercentage of 5193nPercentage of 5784Relative percentage changeAbsolute percentage changeP-value for changea
 Lipid lowering drugs159630.7233540.431.49.60.002
 Last FSC >5 mmol/l136126.2185432.122.35.8<0.0001
 Obesity92917.9114619.810.81.90.030
 Current smoker93718.079713.8−23.6−4.3
 BP <140/85 mmHg228844.1294050.815.46.80.002
 BP <160/90 mmHg398776.8465280.44.83.70.018
 Had MI but not on β-blockersb55940.654734.5−14.9−6.10.240
 On aspirin388074.7458379.26.04.50.004
 Not on aspirin, and no contraindications101519.591915.9−18.7−3.70.005
Group B: diabetes or hypertensionnPercentage of 7288nPercentage of 8374Relative percentage changeAbsolute percentage changeP-value for changea
 Lipid lowering drugs4656.47488.940.02.6<0.001
 Last FSC >5 mmol/l192926.5323538.646.012.20.741
 Obesity176424.2218226.17.71.90.042
 Current smoker125417.3112013.4−22.3−3.8
 BP <140/85 mmHg184025.2263831.524.86.30.001
 BP <160/90 mmHg468464.3594070.910.46.70.003
 On aspirin235532.3290434.77.32.40.093
Group C: remaining populationnPercentage of 42 086Percentage of 42 827Relative percentage changeAbsolute percentage changeP-value for changea
 Lipid lowering drugs3980.94221.04.20.00.669
 Last FSC >5 mmol/l31697.542599.932.12.40.242
 Obesity434610.3487811.410.31.10.013
 Current smoker938822.3756217.7−20.8−4.6
 BP <140/85 mmHg22 00852.324 30956.88.54.50.003
 BP <160/90 mmHg30 80773.233 07577.25.54.00.008
 On aspirin10 02023.810 47124.42.70.60.088

  • ↵a P-value from corrected χ2 test, taking clustering by practice into account. Only those with a recorded value have been included in the analysis.

  • ↵b Percentage is of those with a myocardial infarction. BP = blood pressure. MI = myocardial infarction. FSC = fasting serum cholesterol.